English | 繁體

Search in the results

UM

Browse/Search Results:  1-3 of 3 Help

Selected(0)Clear Items/Page:    Sort:
Targeting STAT3-VISTA axis to suppress tumor aggression and burden in acute myeloid leukemia Journal article
Mo, Jianshan, Deng, Lin, Peng, Keren, Ouyang, Shumin, Ding, Wen, Lou, Linlin, Lin, Ziyou, Zhu, Jianzheng, Li, Jingwei, Zhang, Qiyi, Wang, Pengyan, Wen, Yuanzhen, Chen, Xiaobing, Yue, Peibin, Lu, Jin Jian, Zhu, Kai, Zheng, Yongjiang, Wang, Yuanxiang, Zhang, Xiaolei. Targeting STAT3-VISTA axis to suppress tumor aggression and burden in acute myeloid leukemia[J]. Journal of Hematology & Oncology, 2023, 16(1), 15.
Authors:  Mo, Jianshan;  Deng, Lin;  Peng, Keren;  Ouyang, Shumin;  Ding, Wen; et al.
Favorite | TC[WOS]:15 TC[Scopus]:14  IF:29.5/26.9 | Submit date：2023/03/06
Aml  Immunotherapy  Stat3 Inhibitor  Vista  
Metabolic Reprogramming Driven by IGF2BP3 Promotes Acquired Resistance to EGFR Inhibitors in Non-Small Cell Lung Cancer Journal article
Lin,Ziyou, Li,Jingwei, Zhang,Jian, Feng,Weineng, Lu,Jiaye, Ma,Xiaofan, Ding,Wen, Ouyang,Shumin, Lu,Jinjian, Yue,Peibin, Wan,Guohui, Liu,Peiqing, Zhang,Xiaolei. Metabolic Reprogramming Driven by IGF2BP3 Promotes Acquired Resistance to EGFR Inhibitors in Non-Small Cell Lung Cancer[J]. Cancer research, 2023, 83(13), 2187-2207.
Authors:  Lin,Ziyou;  Li,Jingwei;  Zhang,Jian;  Feng,Weineng;  Lu,Jiaye; et al.
Favorite | TC[WOS]:31 TC[Scopus]:30  IF:12.5/11.6 | Submit date：2023/08/03
Reprogramming of TAMs via the STAT3/CD47-SIRPα axis promotes acquired resistance to EGFR-TKIs in lung cancer Journal article
Lu, Jiaye, Li, Jingwei, Lin, Ziyou, Li, Huaxuan, Lou, Linlin, Ding, Wen, Ouyang, Shumin, Wu, Yonghui, Wen, Yuanzhen, Chen, Xiaobing, Yue, Peibin, Wang, Yuanxiang, Liu, Peiqing, Lu, Jinjian, Zhang, Jian, Feng, Weineng, Zhang, Xiaolei. Reprogramming of TAMs via the STAT3/CD47-SIRPα axis promotes acquired resistance to EGFR-TKIs in lung cancer[J]. Cancer Letters, 2023, 564, 216205.
Authors:  Lu, Jiaye;  Li, Jingwei;  Lin, Ziyou;  Li, Huaxuan;  Lou, Linlin; et al.
Favorite | TC[WOS]:25 TC[Scopus]:25  IF:9.1/8.3 | Submit date：2023/07/20
Acquired Tki Resistance  Cd47  Lung Cancer  Stat3  Tams